These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Differentiation between benign and malignant breast lesions using quantitative diffusion-weighted sequence on 3 T MRI. Tan SL, Rahmat K, Rozalli FI, Mohd-Shah MN, Aziz YF, Yip CH, Vijayananthan A, Ng KH. Clin Radiol; 2014 Jan; 69(1):63-71. PubMed ID: 24156797 [Abstract] [Full Text] [Related]
27. Assessment of early response to concurrent chemoradiotherapy in cervical cancer: value of diffusion-weighted and dynamic contrast-enhanced MR imaging. Park JJ, Kim CK, Park SY, Simonetti AW, Kim E, Park BK, Huh SJ. Magn Reson Imaging; 2014 Oct; 32(8):993-1000. PubMed ID: 24970025 [Abstract] [Full Text] [Related]
29. Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. Port RE, Bernstein LJ, Barboriak DP, Xu L, Roberts TP, van Bruggen N. Magn Reson Med; 2010 Aug; 64(2):408-17. PubMed ID: 20665785 [Abstract] [Full Text] [Related]
31. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF. J Vasc Interv Radiol; 2007 Aug; 18(8):957-63. PubMed ID: 17675611 [Abstract] [Full Text] [Related]
32. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. Hsu YH, Ferl GZ, Ng CM. Magn Reson Imaging; 2013 May; 31(4):618-23. PubMed ID: 23200680 [Abstract] [Full Text] [Related]
34. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment. Yamasaki F, Kurisu K, Aoki T, Yamanaka M, Kajiwara Y, Watanabe Y, Takayasu T, Akiyama Y, Sugiyama K. Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373 [Abstract] [Full Text] [Related]